Recombinant Mouse IGF1 protein (rFc Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1939

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse IGF-1 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse IGF-1 protein Gly33-Ala102 (Accession# Q8CAR0) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 16000
• Accession: Q8CAR0
• PredictedSize: 34.9 kDa
• SDS-PAGE: 32-42 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

Insulin-like-growth factor 1 (IGF-1), a 70 amino-acid peptide hormone is the principal mediator of biochemical effects of growth hormone (GH). IGF-1 is an important growth factor in the regulation of cell proliferation and differentiation. IGF-1 is largely synthesized in the liver (75%) and, to a lesser extent, in peripheral tissues. IGF-1 have been shown to play an essential role in preventing the formation of fatty liver. IGF-1 is a potent mitogen and is inhibited by IGF-binding protein-3 (IGFBP3). High serum IGF-1 and low IGFBP3 are associated with increased risk of several carcinomas. Mice lacking IGF-1 exhibit generalized organ hypoplasia including underdevelopment of the central nervous system and developmental defects in bone, muscle and reproductive systems.

References:

1. Adamo ML. et al. (1993). Adv Exp Med Biol. 343:1-11.
2. Adachi Y. et al. (2019). J Gastroenterol Hepatol. 34(12):2104-2111.
3. Anisimov VN. et al. (2019). Crit Rev Oncol Hematol. 87(3):201-23.
4. Sonntag WE. et al. (2012). J Gerontol A Biol Sci Med Sci. 67(6):587-98.